GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

GH Research PLC

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GH Research (GHRS – Research Report) and COMPASS Pat...

Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and COMPASS Pathways (CMPS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on GH Research (GHRS – Research Report), Viking Therape...

Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), Viking Therapeutics (VKTX)

RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research today and set a price target of $40.00. According to TipRanks, Abrahams i...

RBC Capital Remains a Buy on GH Research (GHRS)

GH Research ( ($GHRS) ) has shared an announcement. On January 13, 2026, GH Research PLC announced that it would present clinical results from its ...

GH Research Showcases Positive GH001 Phase 2b Data in Treatment-Resistant Depression at ACNP 2026

RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on January 5 and set a price target of $33.00. The company’s shares close...

RBC Capital Sticks to Their Buy Rating for GH Research (GHRS)

GH Research ( ($GHRS) ) just unveiled an update. On January 5, 2026, GH Research announced that the U.S. Food and Drug Administration lifted the cl...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GHRS	$15.65	-1.07%	104.31K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GHRS	$15.65	-1.1%	104.31K
3
4
5
6

GHRS

GHRS

Get GH Research PLC Data in Excel

Get GH Research PLC Data in Excel